0QDU

Abliva Ab (0QDU)

Abliva Ab

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:LSE:0QDU

日付	受信時刻	ニュースソース	見出し	コード	企業名
2020/02/19	17 : 03	PR Newswire (US)	NeuroVive Pharmaceutical AB Year End Report January - December 2019	LSE:0QDU	Abliva Ab
2020/02/19	17 : 01	PR Newswire (US)	NeuroVive Pharmaceutical AB Year End Report January - December 2019	LSE:0QDU	Abliva Ab
2019/12/20	23 : 44	PR Newswire (US)	NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study	LSE:0QDU	Abliva Ab
2019/12/20	23 : 40	PR Newswire (US)	NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study	LSE:0QDU	Abliva Ab
2019/12/16	19 : 21	PR Newswire (US)	NeuroVive Announces Settlement in Dispute With CicloMulsion AG	LSE:0QDU	Abliva Ab
2019/12/16	19 : 19	PR Newswire (US)	NeuroVive Announces Settlement in Dispute With CicloMulsion AG	LSE:0QDU	Abliva Ab
2019/11/20	17 : 04	PR Newswire (US)	NeuroVive Pharmaceutical AB Interim Report January - September 2019	LSE:0QDU	Abliva Ab
2019/11/20	16 : 58	PR Newswire (US)	NeuroVive Pharmaceutical AB Interim Report January - September 2019	LSE:0QDU	Abliva Ab
2019/08/21	15 : 55	PR Newswire (US)	NeuroVive Pharmaceutical AB Interim Report January - June 2019	LSE:0QDU	Abliva Ab
2019/08/21	15 : 52	PR Newswire (US)	NeuroVive Pharmaceutical AB Interim Report January - June 2019	LSE:0QDU	Abliva Ab
2019/08/20	20 : 23	PR Newswire (US)	Save the Date: NeuroVive to host Capital Markets Day in Stockholm on 9 October, 2019	LSE:0QDU	Abliva Ab
2019/07/27	20 : 38	PR Newswire (US)	NeuroVive's NeuroSTAT Project Receives FDA Fast Track Designation	LSE:0QDU	Abliva Ab
2019/07/27	20 : 35	PR Newswire (US)	NeuroVive's NeuroSTAT Project Receives FDA Fast Track Designation	LSE:0QDU	Abliva Ab
2019/07/04	21 : 46	PR Newswire (US)	NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical Study	LSE:0QDU	Abliva Ab
2019/07/04	21 : 45	PR Newswire (US)	NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical Study	LSE:0QDU	Abliva Ab
2019/05/21	15 : 45	PR Newswire (US)	NeuroVive Pharmaceutical AB Interim Report January - March 2019	LSE:0QDU	Abliva Ab
2019/05/10	15 : 48	PR Newswire (US)	NeuroVive's IND for Clinical Development of NeuroSTAT Approved by FDA	LSE:0QDU	Abliva Ab
2019/05/10	15 : 46	PR Newswire (US)	NeuroVive's IND for Clinical Development of NeuroSTAT Approved by FDA	LSE:0QDU	Abliva Ab
2019/03/25	18 : 48	PR Newswire (US)	NeuroVive Pharmaceutical AB Publishes 2018 Annual Report	LSE:0QDU	Abliva Ab
2019/03/25	18 : 43	PR Newswire (US)	NeuroVive Pharmaceutical AB Publishes 2018 Annual Report	LSE:0QDU	Abliva Ab
2019/03/07	17 : 07	PR Newswire (US)	NeuroVive Receives SEK 28.2 Million in a Directed New Share Issue	LSE:0QDU	Abliva Ab
2019/02/21	16 : 52	PR Newswire (US)	NeuroVive Enters Commercial Partnership With Oroboros Instruments on Mitochondrial Medicine Research Compounds	LSE:0QDU	Abliva Ab
2018/11/15	20 : 25	PR Newswire (US)	NeuroVive Receives Vinnova Funding to Support Development of NV354, a Novel Treatment for Genetic Mitochondrial Disorders	LSE:0QDU	Abliva Ab
2018/11/15	20 : 21	PR Newswire (US)	NeuroVive Receives Vinnova Funding to Support Development of NV354, a Novel Treatment for Genetic Mitochondrial Disorders	LSE:0QDU	Abliva Ab
2018/10/31	17 : 07	PR Newswire (US)	NeuroVive Today Announces That the Subscription Period for Warrants of Series 2018:1 Will Begin on Thursday, November 1	LSE:0QDU	Abliva Ab
2018/10/04	15 : 50	PR Newswire (US)	NeuroVive Reports First NeuroSTAT Clinical Efficacy Signal in TBI	LSE:0QDU	Abliva Ab
2018/10/04	15 : 45	PR Newswire (US)	NeuroVive Reports First NeuroSTAT Clinical Efficacy Signal in TBI	LSE:0QDU	Abliva Ab
2017/12/11	19 : 41	PR Newswire (US)	NeuroVive Reports Promising Progress in its Clinical Project for Genetic Mitochondrial Diseases, KL1333	LSE:0QDU	Abliva Ab
2017/12/11	19 : 38	PR Newswire (US)	NeuroVive Reports Promising Progress in its Clinical Project for Genetic Mitochondrial Diseases, KL1333	LSE:0QDU	Abliva Ab